文献速递脑血管病

移动卒中单元与常规诊疗对急性缺血性卒中管理的比较:一项系统综述与荟萃分析

Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Neurol · 2022-01-01

该系统综述与荟萃分析比较移动卒中单元(MSU)与常规诊疗对急性缺血性卒中患者功能结局的影响,纳入多项研究。结果显示MSU与更优的功能结局相关(调整OR 1.64),并缩短发病至静脉溶栓时间约31分钟,未增加死亡或症状性颅内出血风险。

要点

  • MSU与常规诊疗相比,90天极佳结局(mRS 0-1)的调整OR为1.64。
  • MSU使发病至静脉溶栓时间中位数缩短31分钟。
  • MSU未增加7天或90天全因死亡及症状性颅内出血风险。

核心结论

  • 与常规诊疗相比,MSU的使用与极佳结局的比值增加约65%相关,并使发病至静脉溶栓时间缩短30分钟,且无安全性顾虑。
  • 这些结果应有助于指南编写委员会和政策制定者。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Cochrane图书馆和Embase从1960年至2021年的文献。
  • 纳入比较MSU部署与常规诊疗用于疑似卒中患者的研究,排除病例系列和病例对照研究。
  • 由2名观察者独立提取数据,遵循PRISMA和MOOSE报告指南,使用ROBINS-I和RoB2工具评估偏倚风险,数据采用随机效应荟萃分析合并。

主要发现

  • 与常规诊疗相比,MSU使用与极佳结局相关(调整OR 1.64;95%CI 1.27-2.13;P < .001;5项研究;n=3228)。
  • MSU使用与全范围mRS上的残疾减少相关(调整共同OR 1.39;95%CI 1.14-1.70;P = .001;3项研究;n=1563)。
  • MSU使用与良好结局相关(mRS 0-2分:粗OR 1.25;95%CI 1.09-1.44;P = .001;6项研究;n=3266)。
  • MSU使用与更短的发病至静脉溶栓时间相关(中位数减少31分钟[95%CI 23-39];P < .001;13项研究;n=3322)。
  • MSU使用与静脉溶栓实施相关(粗OR 1.83;95%CI 1.58-2.12;P < .001;7项研究;n=4790),以及与症状发作60分钟内静脉溶栓相关(粗OR 7.71;95%CI 4.17-14.25;P < .001;8项研究;n=3351)。

关键数值与推荐

  • 主要结局为90天改良Rankin量表(mRS)评分为0至1分的极佳结局。
  • MSU使用与7天或90天全因死亡风险增加无关,也与静脉溶栓后症状性颅内出血比例升高无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: So far, uncertainty remains as to whether there is sufficient cumulative evidence that mobile stroke unit (MSU; specialized ambulance equipped with computed tomography scanner, point-of-care laboratory, and neurological expertise) use leads to better functional outcomes compared with usual care. OBJECTIVE: To determine with a systematic review and meta-analysis of the literature whether MSU use is associated with better functional outcomes in patients with acute ischemic stroke (AIS). DATA SOURCES: MEDLINE, Cochrane Library, and Embase from 1960 to 2021. STUDY SELECTION: Studies comparing MSU deployment and usual care for patients with suspected stroke were eligible for analysis, excluding case series and case-control studies. DATA EXTRACTION AND SYNTHESIS: Independent data extraction by 2 observers, following the PRISMA and MOOSE reporting guidelines. The risk of bias in each study was determined using the ROBINS-I and RoB2 tools. In the case of articles with partially overlapping study populations, unpublished disentangled results were obtained. Data were pooled in random-effects meta-analyses. MAIN OUTCOMES AND MEASURES: The primary outcome was excellent outcome as measured with the modified Rankin Scale (mRS; score of 0 to 1 at 90 days). RESULTS: Compared with usual care, MSU use was associated with excellent outcome (adjusted odds ratio [OR], 1.64; 95% CI, 1.27-2.13; P < .001; 5 studies; n = 3228), reduced disability over the full range of the mRS (adjusted common OR, 1.39; 95% CI, 1.14-1.70; P = .001; 3 studies; n = 1563), good outcome (mRS score of 0 to 2: crude OR, 1.25; 95% CI, 1.09-1.44; P = .001; 6 studies; n = 3266), shorter onset-to-intravenous thrombolysis (IVT) times (median reduction, 31 minutes [95% CI, 23-39]; P < .001; 13 studies; n = 3322), delivery of IVT (crude OR, 1.83; 95% CI, 1.58-2.12; P < .001; 7 studies; n = 4790), and IVT within 60 minutes of symptom onset (crude OR, 7.71; 95% CI, 4.17-14.25; P < .001; 8 studies; n = 3351). MSU use was not associated with an increased risk of all-cause mortality at 7 days or at 90 days or with higher proportions of symptomatic intracranial hemorrhage after IVT. CONCLUSIONS AND RELEVANCE: Compared with usual care, MSU use was associated with an approximately 65% increase in the odds of excellent outcome and a 30-minute reduction in onset-to-IVT times, without safety concerns. These results should help guideline writing committees and policy makers.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Turc G, Hadziahmetovic M, Walter S, et al. Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management: A Systematic Review and Meta-analysis. JAMA Neurol. 2022. PMID: 35129584. doi:10.1001/jamaneurol.2021.5321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。